170 related articles for article (PubMed ID: 9602953)
1. Balanced designs in longitudinal population pharmacokinetic studies.
Ette EI; Sun H; Ludden TM
J Clin Pharmacol; 1998 May; 38(5):417-23. PubMed ID: 9602953
[TBL] [Abstract][Full Text] [Related]
2. Designing population pharmacokinetic studies: performance of mixed designs.
Fadiran EO; Jones CD; Ette EI
Eur J Drug Metab Pharmacokinet; 2000; 25(3-4):231-9. PubMed ID: 11420896
[TBL] [Abstract][Full Text] [Related]
3. Ignorability and parameter estimation in longitudinal pharmacokinetic studies.
Ette EI; Sun H; Ludden TM
J Clin Pharmacol; 1998 Mar; 38(3):221-6. PubMed ID: 9549660
[TBL] [Abstract][Full Text] [Related]
4. On the recording of sample times and parameter estimation from repeated measures pharmacokinetic data.
Sun H; Ette EI; Ludden TM
J Pharmacokinet Biopharm; 1996 Dec; 24(6):637-50. PubMed ID: 9300354
[TBL] [Abstract][Full Text] [Related]
5. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
7. Estimating inestimable standard errors in population pharmacokinetic studies: the bootstrap with Winsorization.
Ette EI; Onyiah LC
Eur J Drug Metab Pharmacokinet; 2002; 27(3):213-24. PubMed ID: 12365204
[TBL] [Abstract][Full Text] [Related]
8. Investigating the contribution of residual unexplained variability components on bias and imprecision of parameter estimates in population pharmacokinetic mixed-effects modeling.
Jaber MM; Brundage RC
J Pharmacokinet Pharmacodyn; 2023 Apr; 50(2):123-132. PubMed ID: 36617366
[TBL] [Abstract][Full Text] [Related]
9. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
Mu S; Ludden TM
J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
[TBL] [Abstract][Full Text] [Related]
10. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.
Ette EI; Howie CA; Kelman AW; Whiting B
Pharm Res; 1995 May; 12(5):729-37. PubMed ID: 7479560
[TBL] [Abstract][Full Text] [Related]
11. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
Chan PL; Nutt JG; Holford NH
J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):307-31. PubMed ID: 16320098
[TBL] [Abstract][Full Text] [Related]
12. Experimental design and efficient parameter estimation in population pharmacokinetics.
al-Banna MK; Kelman AW; Whiting B
J Pharmacokinet Biopharm; 1990 Aug; 18(4):347-60. PubMed ID: 2231324
[TBL] [Abstract][Full Text] [Related]
13. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of population D-optimal designs via pharmacokinetic simulations.
Hooker AC; Foracchia M; Dodds MG; Vicini P
Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
[TBL] [Abstract][Full Text] [Related]
15. Analysis of animal pharmacokinetic data: performance of the one point per animal design.
Ette EI; Kelman AW; Howie CA; Whiting B
J Pharmacokinet Biopharm; 1995 Dec; 23(6):551-66. PubMed ID: 8733946
[TBL] [Abstract][Full Text] [Related]
16. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.
Ogungbenro K; Aarons L
J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118
[TBL] [Abstract][Full Text] [Related]
17. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments.
Ogungbenro K; Aarons L; Graham G
J Biopharm Stat; 2006; 16(2):135-50. PubMed ID: 16584063
[TBL] [Abstract][Full Text] [Related]
18. A reduction in between subject variability is not mandatory for selecting a new covariate.
Lagishetty CV; Vajjah P; Duffull SB
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of fluconazole in people with HIV infection: a population analysis.
McLachlan AJ; Tett SE
Br J Clin Pharmacol; 1996 Apr; 41(4):291-8. PubMed ID: 8730974
[TBL] [Abstract][Full Text] [Related]
20. Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs.
Wolfsegger MJ; Jaki T
J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):479-94. PubMed ID: 19847629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
